美国FDA批准张锋公司的基因编辑临床试验

原文始发于微信公众号(药时代):美国FDA批准张锋公司的基因编辑临床试验

美国FDA批准张锋公司的基因编辑临床试验

(图片来源:MIT官方网站)

2018年11月30日,张锋创建的全球领先的基因组编辑公司Editas Medicine, Inc.纳斯达克股票代码:EDIT)宣布,美国食品药品监督管理局FDA)已接受该公司的EDIT-101的IND申请,允许其开展基因编辑临床试验,目标适应症为Leber先天性黑蒙10型(LCA10)眼病。

Editas Medicine总裁兼首席执行官Katrine Bosley表示:“FDA对EDIT-101 IND申请的接受是基因编辑领域的一个关键时刻,对患者来说是一个重要的里程碑,因为我们现在距离LCA10治疗更近了一步。对我们来说,这是一个真正令人兴奋的时刻!我们期待着作为一家临床阶段研发公司开启我们的下一章,利用CRISPR技术的力量来改变世界各地严重疾病患者的生活。”

随着IND的接受,Editas Medicine已经从合作伙伴Allergan获得了2500万美元的里程碑付款,作为两家公司发现和开发针对严重威胁视力的疾病的实验性眼科药物的合作的一部分。 这是一项1/2期开放标签、剂量递增临床试验,预计招募10至20名患者,以评估安全性、耐受性和 EDIT-101的疗效。

美国FDA批准张锋公司的基因编辑临床试验

欢迎阅读新闻稿!

Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101

EDIT-101 set to be the firstin vivoCRISPR medicine administered to people anywhere in the world

Earns$25 millionmilestone for IND acceptance from partnerAllergan

CAMBRIDGE, Mass.,Nov. 30, 2018(GLOBE NEWSWIRE) — Editas Medicine, Inc.(NASDAQ: EDIT), a leading genome editing company, today announced theU.S. Food and Drug Administration(FDA) has accepted the Company’s Investigational New Drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10).

“The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,” saidKatrine Bosley, President and Chief Executive Officer,Editas Medicine. “This moment is a truly exciting one for us, and we look forward to embarking on our next chapter as a clinical stage company, harnessing the power of CRISPR technology to transform the lives of people with serious diseases around the world.”

With the IND acceptance,Editas Medicinehas earned a$25 millionmilestone payment fromAllerganas part of the alliance between the companies to discover and develop experimental ocular medicines targeting serious, vision-threatening diseases.Editas Medicineand its partner,Allergan Pharmaceuticals International Limited(Allergan), a wholly-owned subsidiary ofAllergan plc, expect to enroll 10 to 20 patients in a Phase 1/2 open label, dose escalation study to evaluate the safety, tolerability, and efficacy of EDIT-101.

About EDIT-101EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber Congenital Amaurosis type 10 (LCA10).EDIT-101 is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells.

About Leber Congenital AmaurosisLeber Congenital Amaurosis, or LCA, is a group of inherited retinal degenerative disorders caused by mutations in at least 18 different genes.It is the most common cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide.Symptoms of LCA appear within the first years of life, resulting in significant vision loss and potentially blindness.The most common form of the disease, LCA10, is a monogenic disorder caused by mutations in the CEP290 gene and is the cause of disease in approximately 20‑30 percent of all LCA patients.

AboutThe Editas Medicine-Allergan AllianceInMarch 2017,Editas MedicineandAllergan Pharmaceuticals International Limited(Allergan) entered a strategic alliance and option agreement under whichAllerganreceived exclusive access and the option to license up to five of Editas Medicine’s genome editing programs for ocular diseases, including EDIT-101.Under the terms of the agreement,Allerganis responsible for development and commercialization of optioned products, subject to Editas Medicine’s option to co-develop and share equally in the profits and losses of two optioned products in the United States.InAugust 2018,Allerganexercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally,Editas Medicineexercised its option to co-develop and share equally in the profits and losses from EDIT-101 inthe United States.Editas Medicineis also eligible to receive development and commercial milestones, as well as royalty payments on a per-program basis.The agreement covers a range of first-in-class ocular programs targeting serious, vision-threatening diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a).

AboutEditas MedicineAs a leading genome editing company,Editas Medicineis focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.Editas Medicineaims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visitwww.editasmedicine.com.

美国FDA批准张锋公司的基因编辑临床试验

美国FDA批准张锋公司的基因编辑临床试验

有深度有温度的医药研发公众号

美国FDA批准张锋公司的基因编辑临床试验美国FDA批准张锋公司的基因编辑临床试验

推 荐 阅 读

刷屏的广谱抗癌药拉罗替尼(larotrectinib,Vitrakvi)之英文说明书

里程碑!针对17种癌症有效的传奇抗癌药LOXO-101震撼获批!这7个问题一定要了解!

卫健委和深圳科技创新委员会关于“基因编辑婴儿”的回应 | 附视频

中国生物化学的巨人是怎样炼成的?

2018全球癌症年报出炉!中国癌症发病率、死亡率全球第一,早癌筛查刻不容缓!

重磅 | K药进医保深圳或第一!

拿破仑·费拉拉和VEGF,离诺奖到底有多远?

重磅乙肝新药获批,研发助力,吉利德邀你加入治愈梦之队

一个伟大的分子

全球抗肿瘤新药高峰论坛顺利召开!

2018年EGFR T790M的全球竞争格局

未来5年最畅销的肿瘤药物TOP10预测及趋势走向

新药!二代PD1进入中国!

Keytruda二线治疗食管癌临床试验达到OS主要终点

新药火热的今天,回顾史上最大医学灾难

重磅 |《中华人民共和国疫苗管理法(征求意见稿)》公开征求您的意见

肝癌患者的福音!FDA批准Keytruda治疗晚期肝细胞癌

海正药业董事长白骅先生辞职

视频 |沪出台“鼓励药械创新32条”,建设全球领先的生物医药创新研发高地!

礼来4000万美元牵手陈列平博士创办的NextCure公司,打造下一代肿瘤免疫疗法

网络研讨会 l药明康德肿瘤细胞系筛选检测平台

2018年全球25大生物技术公司恒瑞国药药明康德云南白药华润上榜

重磅!临床试验默示许可制度正式落地!可喜可贺!

科学家的司机

刚刚!药品管理法(修正草案)征求意见,全文公布

无需临床!直接上市!CDE发布第一批临床急需境外新药名单

创新至上数据为王!“药时代”专访CAS总裁曼努埃尔•古兹曼先生

美国第一个砒霜注射液仿制药上市!费森尤斯卡比推出白血病药物三氧化二砷注射液

在华进行的轻中度阿尔茨海默病患者三期临床试验表明新药可以改善认知能力

关注 |药品管理法修正草案未被通过

重磅发布!国家2018版基药目录

陈列平教授:癌症免疫疗法的正常化

FDA局长倡议仿制药全球批准中国应当如何回应?

华人学者发现治疗白血病的全新靶点 |前沿

上海发布针对肺癌、大肠癌、肝癌、胃癌、乳腺癌、宫颈癌、前列腺癌等7种高发癌症的早筛和预防指南

2019年科学突破奖揭晓 |庄小威、陈志坚获“生命科学突破奖”,许晨阳获“数学新视野奖”

原创 |喜树碱老兵新传

干货 |如何成为一名优秀的BD

喜讯!17种抗癌药纳入国家医保,平均降幅达56.7%,均低于周边国家或地区价格!

数风流人物,也看CFO!

Me-NDA,中国新药研发的新模式?

陈列平教授最新Cell文章 |癌症免疫疗法的范式转变:从免疫增强到免疫正常化

全球生物技术将持续升温上海有望成为世界第二大生物技术中心

李小加:香港生物科技板块的启航

在苏州,我们看到中国新药研发的春天!热烈祝贺第三届“医药创新与投资大会”在苏州隆重举办!

从制药界的视角看今年生物诺奖的争议

2018年诺贝尔化学奖揭晓!得主为Arnold,Smith,Winter!

2018年诺贝尔物理学奖揭晓:美法加三名科学家因激光物理获奖

遗憾无缘诺奖!华人科学家陈列平这样解释癌症免疫疗法

传奇诺奖得主!詹姆斯·艾利森,一位科学家和音乐家!

为何华人科学家陈列平与诺奖失之交臂评委会给出回应

2018年诺贝尔生理学或医学奖揭晓!James Allison和Tasuku Honjo获奖!

诺奖32周年 ||神经生长因子发现及成药记(镇痛—抗癌—神奇眼药水)

中国唯一获批肺癌适应症的PD-1抑制剂Opdivo终于上市了!

欧开了!狄达了!沃来了!|首个免疫肿瘤治疗药物欧狄沃™(Opdivo®)领衔登陆中国市场!

原创首发 | NASH新药研发的一些深度思考

Opdivo第3季度正式开卖,开启中国肺癌治疗新时代

定了!欧狄沃(O药)定价9260RMB(100mg),28日将在中国多城市开售

CCTV |国内首个PD-1抑制剂获批上市,惠及晚期非小细胞肺癌患者

Keytruda的故事

干货!极简PD-1漫画!简到崩溃,干到落泪!

干货!极简CAR-T漫画!简到崩溃,干到落泪!

默沙东PD-1抑制剂帕博利珠单抗在华获批

重磅消息:治好了美国前总统卡特的神奇抗癌药Keytruda,正式在中国上市!

【重磅新闻!】美国前总统吉米卡特脑部癌细胞消失,让世界再次聚焦PD-1/PD-L1重磅炸弹!

这些文章阅读总量过百万,您都看过吗?

美国FDA批准张锋公司的基因编辑临床试验

美国FDA批准张锋公司的基因编辑临床试验

欢迎联系我们!drugtimes@qq.com;微信27674131

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部